ClinicalTrials.gg
Active, not recruitingNCT04025879Updated Aug 26, 2026Results posted

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

A Phase 3 interventional study of Nivolumab and Carboplatin in Carcinoma, Non-Small-Cell Lung, sponsored by Bristol-Myers Squibb. Active, not recruiting at 108 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
16th of 120
461 · median 66
Started
2019
with 8 others
Phase 3
24 of 120
3 open now
Primary completion
2023-07
later than 1 of 43 live
Registered
77th of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment, is one of 9 that started in 2019, is one of 24 in phase 3, reaches primary completion later than 1 of the 43 other live ones, and was the 77th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with suspected or confirmed Stage IIA (> 4 cm) to IIIB (T3N2) non-small cell lung carcinoma (NSCLC) with disease that is considered resectable
  • No
  • Treatment-naive for NSCLC (no prior systemic anti-cancer treatment)
  • Ability to provide surgical or tumor tissue for biomarkers
  • (ECOG) Performance Status of ≤ 1

Exclusion criteria

Exclusion Criteria:

  • Participants with an active, known or suspected disease
  • Any positive test for virus or virus or (HIV)
  • Any previous anti-cancer treatment including cytotoxic, IO treatment, targeted agents, or radiotherapy for NSCLC
  • Prior treatment with any , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo

    Biological: Nivolumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Docetaxel

  • Placebo comparator
    Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac.

    Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Placebo · Drug: Docetaxel

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS936558

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • DrugPlacebo

    Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS) by BICR

    The length of time from randomization to any of the following events: progression of disease or worsening of disease precluding surgery, if surgery is attempted but gross resection is abandoned due to unresectable tumor or worsening of disease, progression or recurrence of disease after surgery, progression or recurrence of disease without surgery, or death due to any cause. Progression/recurrence will be assessed by BICR per RECIST 1.1. Participants who do not undergo surgery for reason other than progression will be considered to have an event at RECIST 1.1 progression or death

    Time frame: From randomization to disease progression, worsening, recurrence, or death due to any cause (up to approximately 44 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time between the date of randomization and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.

    Time frame: From randomization and the date of death due to any cause.

  2. Pathologic Complete Response (pCR) Rate

    Pathologic complete response (pCR) rate is defined as the percentage of randomized participants with absence of residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).

    Time frame: From randomization up to approximately 44 months

  3. Major Pathological Response (MPR) Rate

    Major pathological response (MPR) rate is defined as the percentage of randomized participants with ≤10% residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).

    Time frame: From randomization up to approximately 44 months

  4. The Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)

  5. The Number of Participants With Serious Adverse Events (SAEs)

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

    Time frame: From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)

  6. The Number of Participants With Select Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select AEs include endocrinopathies, diarrhea/colitis, hepatitis, pneumonitis, interstitial nephritis, and rash. Multiple event terms that may describe each of these were grouped into endocrine, GI, hepatic, pulmonary, renal, and skin select AE categories, respectively. Hypersensitivity/infusion reactions were analyzed along with the select AE categories.

    Time frame: From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)

07

Results

Posted Jul 23, 2024

Participant flow

Randomization
Participant flow — Randomization
MilestoneNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
Started229232
Completed228230
Not completed12
Withdrew: Participant withdrew consent01
Withdrew: Participant no longer met study criteria11
Treatment
Participant flow — Treatment
MilestoneNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
Started228230
Neoadjuvant treatment228230
Adjuvant treatment142152
Completed8592
Not completed143138
Withdrew: Ongoing treatment108
Withdrew: Disease progression/recurrence3672
Withdrew: Study drug toxicity3613
Withdrew: Death20
Withdrew: Adverse event unrelated to study drug2114
Withdrew: Participant request to discontinue study treatment168
Withdrew: Participant withdrew consent13
Withdrew: Participant no longer meets study criteria32
Withdrew: Lost to follow-up10
Withdrew: Other reasons1517
Withdrew: Administrative reason by sponsor01
Withdrew: Not reported20

Outcome measures

PrimaryEvent-Free Survival (EFS) by BICR

The length of time from randomization to any of the following events: progression of disease or worsening of disease precluding surgery, if surgery is attempted but gross resection is abandoned due to unresectable tumor or worsening of disease, progression or recurrence of disease after surgery, progression or recurrence of disease without surgery, or death due to any cause. Progression/recurrence will be assessed by BICR per RECIST 1.1. Participants who do not undergo surgery for reason other than progression will be considered to have an event at RECIST 1.1 progression or death

Time frame:
From randomization to disease progression, worsening, recurrence, or death due to any cause (up to approximately 44 months)
Reported as:
Median · Months
Event-Free Survival (EFS) by BICR
MonthsNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
Event-Free Survival (EFS) by BICRNA (28.94 to —)18.43 (13.63 to 28.06)
Statistical analysis
  • Nivolumab + SOC Chemotherapy vs Placebo + SOC Chemotherapy · Log Rank · p = 0.00025 · Cox proportional hazard: 0.58 · 95% CI 0.43 to 0.78Stratified by randomization stratification factors: PD-L1 Status (\>=1% vs \<1%/not evaluable/indeterminate), disease stage (II vs III), histology (squamous vs non-squamous).
SecondaryOverall Survival (OS)

OS is defined as the time between the date of randomization and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.

Time frame:
From randomization and the date of death due to any cause.

Results for this outcome have not been posted.

SecondaryPathologic Complete Response (pCR) Rate

Pathologic complete response (pCR) rate is defined as the percentage of randomized participants with absence of residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).

Time frame:
From randomization up to approximately 44 months
Reported as:
Number · Percentage of Participants
Pathologic Complete Response (pCR) Rate
Percentage of ParticipantsNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
Pathologic Complete Response (pCR) Rate25.3 (19.8 to 31.5)4.7 (2.4 to 8.3)
Statistical analysis
  • Nivolumab + SOC Chemotherapy vs Placebo + SOC Chemotherapy · Difference of pcr: 20.5 · 95% CI 14.3 to 26.6Strata adjusted difference based on Cochran-Mantel-Haenszel (CMH) method of weighting.
  • Nivolumab + SOC Chemotherapy vs Placebo + SOC Chemotherapy · Odds ratio (or): 6.64 · 95% CI 3.40 to 12.97Strata adjusted odds ratio using Mantel-Haenszel method.
SecondaryMajor Pathological Response (MPR) Rate

Major pathological response (MPR) rate is defined as the percentage of randomized participants with ≤10% residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).

Time frame:
From randomization up to approximately 44 months
Reported as:
Number · Percentage of participants
Major Pathological Response (MPR) Rate
Percentage of participantsNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
Major Pathological Response (MPR) Rate35.4 (29.2 to 41.9)12.1 (8.2 to 17.0)
Statistical analysis
  • Nivolumab + SOC Chemotherapy vs Placebo + SOC Chemotherapy · Difference of mpr: 23.2 · 95% CI 15.8 to 30.6Strata adjusted difference based on Cochran-Mantel-Haenszel (CMH) method of weighting.
  • Nivolumab + SOC Chemotherapy vs Placebo + SOC Chemotherapy · Odds ratio (or): 4.01 · 95% CI 2.48 to 6.49Strata adjusted odds ratio using Mantel-Haenszel method.
SecondaryThe Number of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)
Reported as:
Count of participants · Participants
The Number of Participants With Adverse Events (AEs)
ParticipantsNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
The Number of Participants With Adverse Events (AEs)222225
SecondaryThe Number of Participants With Serious Adverse Events (SAEs)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

Time frame:
From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)
Reported as:
Count of participants · Participants
The Number of Participants With Serious Adverse Events (SAEs)
ParticipantsNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
The Number of Participants With Serious Adverse Events (SAEs)9671
SecondaryThe Number of Participants With Select Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select AEs include endocrinopathies, diarrhea/colitis, hepatitis, pneumonitis, interstitial nephritis, and rash. Multiple event terms that may describe each of these were grouped into endocrine, GI, hepatic, pulmonary, renal, and skin select AE categories, respectively. Hypersensitivity/infusion reactions were analyzed along with the select AE categories.

Time frame:
From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)
Reported as:
Count of participants · Participants
The Number of Participants With Select Adverse Events (AEs)
ParticipantsNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
Gastrointestinal Event3737
Hepatic Event4631
Pulmonary Event178
Renal Event3418
Skin Event7153
Hypersensitivity/Infusion Reaction Event1514
Endocrine Event4213

Adverse events

Collected over All-cause mortality was assessed from randomization to primary completion (up to approximately 44 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 30 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + SOC Chemotherapy40/229 (17.5%)109/228 (47.8%)214/228 (93.9%)
Placebo + SOC Chemotherapy48/232 (20.7%)83/230 (36.1%)212/230 (92.2%)
Most frequent serious events
Showing 10 of 193
Most frequent serious events
EventNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
PneumoniaInfections and infestations9/22810/230
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/2286/230
Acute kidney injuryRenal and urinary disorders5/2281/230
HaemoptysisRespiratory, thoracic and mediastinal disorders5/2283/230
PneumonitisRespiratory, thoracic and mediastinal disorders5/2284/230
ColitisGastrointestinal disorders4/2280/230
COVID-19Infections and infestations4/2282/230
SepsisInfections and infestations4/2280/230
AnaemiaBlood and lymphatic system disorders1/2284/230
Atrial fibrillationCardiac disorders1/2284/230
Most frequent other events
Showing 10 of 56
Most frequent other events
EventNivolumab + SOC ChemotherapyPlacebo + SOC Chemotherapy
AnaemiaBlood and lymphatic system disorders93/22873/230
NauseaGastrointestinal disorders67/22878/230
ConstipationGastrointestinal disorders72/22865/230
FatigueGeneral disorders and administration site conditions67/22858/230
AlopeciaSkin and subcutaneous tissue disorders59/22864/230
CoughRespiratory, thoracic and mediastinal disorders51/22848/230
Decreased appetiteMetabolism and nutrition disorders45/22846/230
ArthralgiaMusculoskeletal and connective tissue disorders45/22842/230
DyspnoeaRespiratory, thoracic and mediastinal disorders39/22836/230
DiarrhoeaGastrointestinal disorders37/22836/230

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nivolumab + SOC ChemotherapyPlacebo + SOC ChemotherapyTotal
<=18 years000
Between 18 and 65 years102100202
>=65 years127132259
Age, Continuous
Age, Continuous(Years)Nivolumab + SOC ChemotherapyPlacebo + SOC ChemotherapyTotal
Mean64.2 ± 7.964.6 ± 8.464.4 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + SOC ChemotherapyPlacebo + SOC ChemotherapyTotal
Female6272134
Male167160327
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab + SOC ChemotherapyPlacebo + SOC ChemotherapyTotal
Hispanic or Latino91726
Not Hispanic or Latino128113241
Unknown or Not Reported92102194
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab + SOC ChemotherapyPlacebo + SOC ChemotherapyTotal
American Indian or Alaska Native000
Asian6650116
Native Hawaiian or Other Pacific Islander000
Black or African American448
White155175330
More than one race000
Unknown or Not Reported437
08

Study locations

108 sites
  • Local Institution - 0104
    Tampa, Florida 33612, United States
  • Local Institution - 0040
    Atlanta, Georgia 30342, United States
  • Local Institution - 0120
    Augusta, Georgia 30912, United States
  • Local Institution - 0145
    Chicago, Illinois 60611, United States
  • Local Institution - 0078
    Chicago, Illinois 60612, United States
  • Local Institution - 0121
    Orland Park, Illinois 60462, United States
  • Rcca Md Llc
    Bethesda, Maryland 20817, United States
  • Local Institution - 0076
    Boston, Massachusetts 02215, United States
  • Local Institution - 0074
    Newton, Massachusetts 02459, United States
  • Local Institution - 0086
    Traverse City, Michigan 49684, United States
  • Local Institution - 0100
    Lebanon, New Hampshire 03756, United States
  • Local Institution - 0055
    Cincinnati, Ohio 45220, United States
  • Local Institution - 0102
    Cleveland, Ohio 44106, United States
  • Local Institution - 0054
    Houston, Texas 77030, United States
  • Local Institution - 0103
    Fredericksburg, Virginia 22408, United States
  • Local Institution - 0043
    Buenos Aires, Buenos Aires CP1280AEB, Argentina
  • Local Institution - 0032
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Local Institution - 0031
    ABB, Buenos Aires F.D. C1199ABB, Argentina
  • Local Institution - 0030
    CABA, 1426, Argentina
  • Local Institution - 0020
    Sydney, New South Wales 2050, Australia
  • Local Institution - 0033
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0122
    Melbourne, Victoria 3065, Australia
  • Local Institution - 0023
    North Ballarat, Victoria 33500, Australia
  • Local Institution - 0002
    Edegem, 2650, Belgium
  • Local Institution - 0005
    Liège, 4000, Belgium
  • Local Institution - 0001
    Roeselare, 8800, Belgium
  • Local Institution - 0035
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0029
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0106
    São Paulo, São Paulo 01321-001, Brazil
  • Local Institution - 0036
    São Paulo, São Paulo 01509-010, Brazil
  • Local Institution - 0034
    São Paulo, São Paulo 05652-900, Brazil
  • Local Institution - 0062
    Oshawa, Ontario L1G 2B9, Canada
  • Local Institution - 0115
    Beijing, Beijing Municipality 100021, China
  • Local Institution - 0096
    Beijing, BEI 100142, China
  • Local Institution - 0137
    Fuzhou, Fujian 350001, China
  • Local Institution - 0136
    Fuzhou, Fujian 350014, China
  • Local Institution - 0151
    Hubei Sheng, Hubei 430079, China
  • Local Institution - 0092
    Changsha, Hunan 410000, China
  • Local Institution - 0093
    Changsha, Hunan 410000, China
  • Local Institution - 0091
    Changsha, Hunan 410008, China
  • Local Institution - 0098
    Shanghai, Shanghai Municipality 200010, China
  • Local Institution - 0165
    Shanghai, Shanghai Municipality 200030, China
  • Local Institution - 0113
    Shanghai, Shanghai Municipality 200433, China
  • Local Institution - 0088
    Chengdu, Sichuan 610041, China
  • Local Institution - 0099
    Hangzhou, Zhejiang 310016, China
  • Local Institution - 0095
    Shanghai, 200032, China
  • Local Institution - 0041
    Prague, 128 08, Czechia
  • Local Institution - 0042
    Prague, 140 59, Czechia
  • Local Institution - 0073
    Besançon, 25030, France
  • Local Institution - 0037
    La Tronche, 38700, France
  • Local Institution - 0050
    Montpellier, 34295, France
  • Local Institution - 0038
    Paris, 75018, France
  • Local Institution - 0051
    Paris, 75970, France
  • Local Institution - 0083
    Rennes, 35033, France
  • Local Institution - 0146
    Rouen, 76000, France
  • Local Institution - 0109
    Immenstadt im Allgäu, Bavaria 87509, Germany
  • Local Institution - 0110
    Cologne, North Rhine-Westphalia 51109, Germany
  • Local Institution - 0085
    Berlin, 13353, Germany
  • Local Institution - 0065
    Frankfurt, 60488, Germany
  • Local Institution - 0072
    Georgsmarienhütte, 49124, Germany
  • Local Institution - 0071
    Hamm, 59063, Germany
  • Local Institution - 0108
    Heidelberg, 69126, Germany
  • Local Institution - 0064
    Löwenstein, 74245, Germany
  • Local Institution - 0147
    Ludwigsburg, 71640, Germany
  • Local Institution - 0063
    Lübeck, 23538, Germany
  • Local Institution - 0070
    Moers, 47441, Germany
  • Local Institution - 0066
    München, 81675, Germany
  • Local Institution - 0016
    Dublin, Dublin D24 DH74, Ireland
  • Local Institution - 0024
    Forlì, 47014, Italy
  • Local Institution - 0026
    Milan, 20122, Italy
  • Local Institution - 0025
    Parma, 43126, Italy
  • Local Institution - 0135
    Nagoya, Aichi-ken 4640021, Japan
  • Local Institution - 0124
    Kashiwa-shi, Chiba 2778577, Japan
  • Local Institution - 0129
    Kitakyushu-shi, Fukuoka 8078556, Japan
  • Local Institution - 0128
    Hiroshima, Hiroshima 734-8551, Japan
  • Local Institution - 0127
    Kobe, Hyōgo 6500047, Japan
  • Local Institution - 0144
    Kanazawa, Ishikawa-ken 9208641, Japan
  • Local Institution - 0125
    Yokohama, Kanagawa 241-8515, Japan
  • Local Institution - 0131
    Sendai, Miyagi 9800873, Japan
  • Local Institution - 0126
    Sakai-shi, Osaka 5918555, Japan
  • Local Institution - 0130
    Kitaadachigun, Saitama 3620806, Japan
  • Local Institution - 0142
    Bunkyo-ku, Tokyo 1138431, Japan
  • Local Institution - 0133
    Bunkyo-ku, Tokyo 1138603, Japan
  • Local Institution - 0143
    Chuo-ku, Tokyo 1040045, Japan
  • Local Institution - 0134
    Chuo-ku, Tokyo 5418567, Japan
  • Local Institution - 0132
    Fukushima, 960-1295, Japan
  • Local Institution - 0028
    Chihuahua City, Chihuahua 31000, Mexico
  • Local Institution - 0077
    Guadalajara, Jalisco 44280, Mexico
  • Local Institution - 0027
    Monterrey, Nuevo León 64460, Mexico
  • Local Institution - 0004
    Groningen, 9700RB, Netherlands
  • Local Institution - 0003
    Rotterdam, 3015 GD, Netherlands
  • Local Institution - 0049
    Krakow, Lesser Poland Voivodeship 31-202, Poland
  • Local Institution - 0117
    Hato Rey, 00917, Puerto Rico
  • Local Institution - 0013
    Cluj-Napoca, Cluj 400015, Romania
  • Local Institution - 0011
    Bucharest, 022328, Romania
  • Local Institution - 0012
    Floreşti, 407280, Romania
  • Local Institution
    Moscow, 115478, Russia
  • Local Institution
    Saint Petersburg, 194291, Russia
  • Local Institution
    Saint Petersburg, 197758, Russia
  • Local Institution
    Saint Petersburg, 198255, Russia

Showing the first 100 of 108 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cascone T, Awad MM, Spicer JD, He J, Lu S, Tanaka F, Cornelissen R, Petruzelka LB, Gao Y, Pujol JL, Ito H, de Oliveira Muniz Koch L, Ciuleanu TE, Wu L, Bohnet S, Watanabe Y, Taube JM, Deutsch JS, Erdmann CC, Meadows-Shropshire S, Neely J, Ip V, Hung YH, Sathyanarayana P, Bhatia S, Chu K, Blum SI, Lucherini S, Eddy N, Yadav A, Provencio M. Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. Nature. 2026 Aug 12. doi: 10.1038/s41586-026-10925-6. Online ahead of print. PubMed 42587156 ↗
  • Provencio M, Awad MM, Spicer JD, Janssens A, Moiseyenko F, Gao Y, Watanabe Y, Alexandru A, Guisier F, Frost N, Franke F, Hiltermann TJN, He J, Tanaka F, Lu S, Coronado Erdmann C, Sathyanarayana P, Tran P, Devas V, Cascone T. Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis. Nat Cancer. 2026 Jan;7(1):169-181. doi: 10.1038/s43018-025-01104-z. Epub 2026 Jan 8. PubMed 41507539 ↗
  • Tanaka F, Watanabe Y, Sugawara S, Okami J, Muto S, Okada M, Horio Y, Tsuboi M, Sato Y, Takamochi K, Horinouchi H, Tambo Y, Seike M, Okishio K, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Ito H. Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T. Cancer Sci. 2026 Mar;117(3):759-768. doi: 10.1111/cas.70300. Epub 2025 Dec 23. PubMed 41431434 ↗
  • Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. PubMed 38749033 ↗
  • Leal TA, Ramalingam SS. Neoadjuvant therapy gains FDA approval in non-small cell lung cancer. Cell Rep Med. 2022 Jul 19;3(7):100691. doi: 10.1016/j.xcrm.2022.100691. PubMed 35858590 ↗
  • Hong WX, Sagiv-Barfi I, Czerwinski DK, Sallets A, Levy R. Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. Cancer Res. 2022 Apr 1;82(7):1396-1408. doi: 10.1158/0008-5472.CAN-21-1382. PubMed 35135810 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jul 2023, 44 months.

Results were first posted in Jul 2024, 11 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 44 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 19, 2019
StartActual
Nov 5, 2019
Primary completionActual
Jul 26, 2023
CompletionEst.
Jul 31, 2027
Results first posted
Jul 23, 2024
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04025879
Responsible party
Sponsor
First posted
Jul 19, 2019
Start date
Nov 5, 2019
Primary completion
Jul 26, 2023
Completion
Jul 31, 2027 (estimated)
Results posted
Jul 23, 2024
Last update
Aug 26, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion